Pharmacokinetics of C-1027 in mice as determined by TCA-RA method

World Journal of Gastroenterology

Volumn 11, Issue 5, 2005, Pages 717-720

  Liu, You Ping ^a,b   Li, Quan Sheng ^a   Huang, Yu Rong ^a   Zhou, Mao Jin ^a,b   Liu, Chang Xiao ^a  

^a TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

C 1027; Pharmacokinetics; TCA RA method

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; LIDAMYCIN; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CRYSTALLIZATION; DRUG CLEARANCE; DRUG DESIGN; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MACROMOLECULE; MALE; MOUSE; NONHUMAN; QUALITY CONTROL; RADIOACTIVITY; SERUM; VALIDATION PROCESS;

EID: 13544261680     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i5.717     Document Type: Article

References (43)

1. Hu JL, Xue YC, Xie MY, Zhang R, Otani T, Minami Y, Yamada Y, Marunaka T. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot 1988; 41: 1575-1579
2. Otani T, Minami Y, Marunaka T, Zhang R, Xie MY. A new macromolecular antitumor antibiotic, C-1027. II. Isolation and physico-chemical properties. J Antibiot 1988; 41: 1580-1585
3. Zhen YS, Ming XY, Yu B, Otani T, Saito H, Yamada Y. A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot 1989; 42: 1294-1298
4. Otani T, Yasuhara T, Minami Y, Shimazu T, Zhang R, Xie MY. Purification and primary structure of C-1027-AG, a selective antagonist of antitumor antibiotic C-1027, from Streptomyces globisporus. Agric Biol Chem 1991; 55: 407-417
5. Liu W, Shen B. Genes for production of the enediyne antitumor antibiotic C-1027 in Streptomyces globisporus are clustered with the cagA gene that encodes the C-1027 apoprotein. Antimicrob Agents Chemother 2000; 44: 382-392
6. Matsumoto T, Okuno Y, Sugiura Y. Specific interaction between a novel enediyne chromophore and apoprotein in macromolecular antitumor antibiotic C-1027. Biochem Biophys Res Commun 1993; 195: 659-666
7. Otani T. Conformation studies on and assessment by spectral analysis of the protein-chromophore interaction of the macromolecular antitumor antibiotic C-1027. J Antibiot 1993; 46: 791-802
8. Chen Y, Shao R, Bartlam M, Li J, Jin L, Gao Y, Liu Y, Tang H, Zhen Y, Rao Z. Crystallization and preliminary X-ray crystallographic studies of a macromolecular antitumour antibiotic, C1027. Acta Crystallogr D Biol Crystallogr 2002; 58(Pt 1): 173-175
9. Tanaka T, Fukuda-Ishisaka S, Hirama M, Otani T. Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J Mol Biol 2001; 309: 267-283
10. Semmelhack MF, Jiang Y, Ho D. Synthesis of the amino sugar from C-1027. Org Lett 2001; 3: 2403-2406
11. Xu YJ, Li DD, Zhen YS. Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells. Cancer Chemother Pharmacol 1990; 27: 41-46
12. He QY, Liang YY, Wang DS, Li DD. Characterization of cell death induced by anticancer antibiotic lidamycin in human hepatoma BEL-7402 cells. Yaoxue Xuebao 2001; 36: 174-178
13. Cui DP, Wang Z, Li DD. Effect of lidamycin on the expression of genes involved in invasion regulation in HCT-8 human colon cancer cells. Yaoxue Xuebao 2001; 36: 246-249
14. He QY, Jiang B, Li DD, Zhen YS. Effects of lidamycin on apoptotic gene expressions and cytoskeleton in human hepatoma bel-7402 cells. Aizheng 2002; 21: 351-355
15. He QY, Jiang B, Li DD. Effects of lidamycin on genomic DNA in human hepatoma BEL-7402 cells. Acta Pharmacol Sin 2002; 23: 253-256
16. He QY, Liang YY, Wang DS, Li DD. Characteristics of mitotic cell death induced by enediyne antibiotic lidamycin in human epithelial tumor cells. Int J Oncol 2002; 20: 261-266
17. Zhen H, Xue Y, Zhen Y. Inhibition of angiogenesis by antitumor antibiotic C1027 and its effect on tumor metastasis. Zhonghua Yixue Zazhi 1997; 77: 657-660
18. Li J, Zhen Y, Yang Z. Biodistribution of monoclonal antibody and Fab fragment and antitumor effect of their conjugates on hepatoma xenografts. Zhongguo Yixuekexueyuan Xuebao 1994; 16: 328-333
19. Sugiura Y. Molecular mechanisms of DNA recognition and function by bioactive compounds. Yakugaku Zasshi 2000; 120: 1409-1418
20. Hiraku Y, Oikawa S, Kawanishi S. Distamycin A, a minor groove binder, changes enediyne-induced DNA cleavage sites and enhances apoptosis. Nucleic Acids Res Suppl 2002: 95-96
21. Wang Z, He Q, Liang Y, Wang D, Li YY, Li D. Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells. Biochem Pharmacol 2003; 65: 1767-1775
22. Dziegielewski J, Beerman TA. Cellular responses to the DNA strand-scission enediyne C-1027 can be independent of ATM, ATR, and DNA-PK kinases. J Biol Chem 2002; 277: 20549-20554
23. McHugh MM, Yin X, Kuo SR, Liu JS, Melendy T, Beerman TA. The cellular response to DNA damage induced by the enediynes C-1027 and neocarzinostatin includes hyperphosphorylation and increased nuclear retention of replication protein a (RPA) and trans inhibition of DNA replication. Biochemistry 2001; 40: 4792-4799
24. McHugh MM, Beerman TA. C-1027-induced alterations in Epstein-Barr viral DNA replication in latently infected cultured human Raji cells: Relationship to DNA damage. Biochemistry 1999; 38: 6962-6970
25. Kirk CA, Goodisman J, Beerman TA, Gawron LS, Dabrowiak JC. Kinetics of cleavage of intra- and extracellular simian virus 40 DNA with the enediyne anticancer drug C-1027. Biophys Chem 1997; 63: 201-209
26. Matsumoto T, Sugiura Y. Alterations of binding mode and cutting site by G->I replacement in preferred cleavage sequences 5′-AGG of chromoprotein C-1027. Biochem Biophys Res Commun 1994; 205: 1533-1538
27. Xu YJ, Zhen YS, Goldberg IH. C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 1994; 33: 5947-5954
28. Zhou CS, Xu LN, Jiang M, Zhen YS. A monoclonal antibody directed against an enediyne antitumor antibiotic and its preliminary application. Yaoxue Xuebao 1997; 32: 28-32
29. Shao RG, Zhen YS. Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity. Yaoxue Xuebao 1995; 30: 336-342
30. Liu JS, Kuo SR, Yin X, Beerman TA, Melendy T. DNA damage by the enediyne C-1027 results in the inhibition of DNA replication by loss of replication protein A function and activation of DNA-dependent protein kinase. Biochemistry 2001; 40: 14661-14668
31. Xu YJ, Xi Z, Zhen YS, Goldberg IH. Mechanism of formation of novel covalent drug DNA interstrand cross-links and monoadducts by enediyne antitumor antibiotics. Biochemistry 1997; 36: 14975-14984
32. Sugiura Y, Totsuka R, Araki M, Okuno Y. Selective cleavages of tRNAPhe with secondary and tertiary structures by enediyne antitumor antibiotics. Bioorg Med Chem 1997; 5: 1229-1234
33. McHugh MM, Beerman TA, Burhans WC. DNA-damaging enediyne C-1027 inhibits initiation of intracellular SV40 DNA replication in trans. Biochemistry 1997; 36: 1003-1009
34. Xu YJ, Xi Z, Zhen YS, Goldberg IH. A single binding mode of activated enediyne C1027 generates two types of double-strand DNA lesions: Deuterium isotope-induced shuttling between adjacent nucleotide target sites. Biochemistry 1995; 34: 12451-12460
35. Totsuka R, Aizawa Y, Uesugi M, Okuno Y, Matsumoto T, Sugiura Y. RNA cleavage by C-1027 chromophore, an enediyne antitumor antibiotic: High selectivity to an anticodon arm. Biochem Biophys Res Commun 1995; 208: 168-173
36. Tang ZM, Liu XW, Xu LP, Shan CW, Song QS. Pharmacokinetics and tissue distribution of human recombinant interleukin-2 in mice. Acta Pharmacologica Sinica 1994; 15: 51-56
37. Sugimoto Y, Otani T, Oie S, Wierzba K, Yamada Y. Mechanism of action of a new macromolecular antitumor antibiotic, C-1027. J Antibiotic 1990; 43: 417-421
38. Liu CX, Wei GL, Li QS. Methodology study of validation for bioanalysis in studies on pharmacokinetics and bioavailability. Asian J Drug Metab Pharmacokinet 2001; 1: 279-286
39. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, Mc Dowall RD, Pittman KA, Spector S. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 1991; 16: 249-255
40. Gao J. Bioanalytical method validation for studies on pharmacokinetics, bioavailability and bioequivalence: Highlights of the FDA's Guidance. Asian J Drug Metab Pharmacokinet 2004; 4: 5-13
41. Xia JH. Validation of analytical methods for pharmacokinetics, boiavailability and bioequivalence studies. Asian J Drug Metab Pharmacokinet 2001; 1: 95-100
42. Liu YP, Zhou MJ. Effect of polyethylene glycol derivation on pharmacokinetic properties of biotechnical drugs. Asian J Drug Metab Pharmacokinet 2002; 2: 127-131
43. Pannell R, Gurewich V. Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-1223